All In Biotech

Free tool

FAERS Monitor: Monistat 3

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018888 or its brand name (Monistat 3, Miconazole Nitrate). Reports on generic versions are filed under their own applications.

Reports

1,906

Serious

792

42% of reports

Hospitalization

331

Death reported

87

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vulvovaginal burning sensation424
  • drug ineffective193
  • vulvovaginal pain184
  • vulvovaginal pruritus147
  • vaginal haemorrhage113
  • condition aggravated97
  • vulvovaginal discomfort96
  • pain77
  • burning sensation72
  • pruritus71
  • off label use64
  • drug interaction60
  • abdominal pain59
  • hypersensitivity55
  • application site pain48

Reports by year received

View as table
YearReports
200420
200515
200621
200712
200838
200957
201037
201150
201280
201325
201430
201531
2016105
201782
2018125
201969
2020116
2021149
2022171
2023119
2024160
2025196
2026198

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,253 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vulvovaginal burning sensationSignal424823.6754.4323,527
vulvovaginal painSignal184438.2380.876,794
vulvovaginal pruritusSignal147329.8281.746,484
vulvovaginal discomfortSignal96245.0201.122,588
vaginal haemorrhageSignal11328.824.13,003
application site painSignal4824.118.21,038
burning sensationSignal7211.39.0670
drug interactionSignal604.23.3143
condition aggravatedSignal973.52.9175
hypersensitivitySignal553.32.585
abdominal painSignal592.82.267
pruritusSignal712.01.637
drug ineffective1931.61.448
pain771.41.18
off label use640.80.63

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.